利用真實世界證據 (RWE)：醫學事務 (MA) 團隊的最佳實踐

真實世界證據 (RWE) 正在透過提供來自日常醫療實踐而非傳統臨床試驗的見解來改變醫療事務 (MA)。 RWE 包括來自電子病歷、保險索賠、病人登記和穿戴式裝置的數據，可以提供對治療結果的廣泛了解。

對於 MA 團隊來說，RWE 對於推動更好的患者結果、提供臨床決策資訊和支援監管提交至關重要。然而，必須解決數據品質、整合和合規性方面的課題。

FirstWord 向製藥業 MA 顧問 Steven Camper 詢問了 MA 團隊克服障礙、確保資料完整性和最大限度地發揮 RWE 對醫療保健影響的策略和最佳實踐。

主要的問題

• 1.請向我們介紹您在 MA 的 RWE 背景和經驗。
• 2.隨著 RWE 重要性的日益增加，您的角色發生了怎樣的變化？
• 3.將RWE成功納入MA策略的關鍵步驟是什麼？
• 4.您的組織或產業中有哪些成功實施 RWE 的例子？
• 5.MA 團隊在使用 RWE 時面臨哪些常見課題？
• 6.您會向 MA 團隊推薦哪些最佳實踐，以最大限度地提高 RWE 的價值？
• 7.我們如何確保RWE的品質與可靠性？
• 8.使用 RWE 時，MA 團隊應考慮哪些監管和道德因素？
• 9.您如何確保遵守這些規定？
• 10.您預見在 MA 中使用 RWE 會出現哪些趨勢？
• 11.MA 團隊如何為這些趨勢做好準備？

我們的報告特色：

FirstWord Reports 是值得信賴的行業領導者，專注於製藥領域，為生物製藥專業人士和決策者提供深入、可操作的見解。我們深厚的行業知識使我們能夠提供相關且有價值的見解，幫助我們的客戶了解新興趨勢並有效地解決複雜的課題。我們的報告以廣泛的研究以及來自領先專家和 KOL 的獨立、公正的見解為後盾，為您提供所需的準確性和可信度。獨家採訪和數據以及持續的市場監控使我們能夠全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域、包括 KOL 洞察和定量醫生調查在內的醫生情報以及行業專家對 MA、數位健康、銷售和行銷、市場准入和其他領域問題的看法，可以幫助您做出更明智的、數據驅動的決策，以在快速變化的行業中保持競爭力。

Real-world evidence (RWE) is transforming medical affairs by providing insights from everyday medical practice, unlike traditional clinical trials. Including data from electronic health records, insurance claims, patient registries and wearable devices, RWE offers a broader understanding of treatment outcomes.

For medical affairs teams, RWE is essential for driving better patient outcomes, informing clinical decisions and supporting regulatory submissions. Challenges arising around data quality, integration and compliance, however, must be addressed.

FirstWord spoke to Stephen Camper, a medical affairs consultant to the pharma industry, about the strategies and best practices medical affairs teams can use to overcome obstacles, ensure data integrity and maximise RWE's impact on healthcare.

Key Questions Answered:

• 1. Can you share a bit about your background and experience with RWE in medical affairs?
• 2. How has your role evolved with the increasing importance of RWE?
• 3. What are the key steps to start successfully integrating RWE into medical affairs strategies?
• 4. Can you provide examples of successful RWE implementation in your organisation or industry?
• 5. What are the common challenges medical affairs teams face when using RWE?
• 6. What best practices would you recommend for medical affairs teams to maximise the value of RWE?
• 7. How can teams ensure the quality and reliability of the RWE they use?
• 8. What regulatory and ethical considerations should medical affairs teams keep in mind when using RWE?
• 9. How do you ensure compliance with these regulations?
• 10. What future trends do you foresee in the use of RWE in medical affairs?
• 11. How can medical affairs teams prepare for these trends?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.